switching between glp-1 agonists 📚There’s a growing trend you’re seeing for a reason: some patients are from medications to dual agonists., This isn’t about hype. It’s about physiology., 🧠 GLP-1 like Semaglutide Science Behind GLP 1 GIP

[5] Unknown Long-Term Consequences The most significant concern is that Ozempic overall is still a relatively new drug, particularly in the context of long-term, non-diabetic use for weight management

Some patients may feel tempted to wait for retatrutide because headlines sound impressive

Right now, there are hundreds of new incretin-based medications in development

Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of beta-amyloid pathology

Deletion of GIP receptor has been found to counteract high-fat diet induced weight gain in mice, suggesting a causal role of GIP in development of obesity [36]

Some patients, termed super-responders, lose more weight than expected